Fengler, K. TCT 580: Initial, Prospective Analysis of Uncontrolled Hypertensive Patients Included in the Global Paradise System (GPS) Registry Outside of the United States. TCT. 2025
https://www.tctmd.com/slide/tct-580-initial-prospective-analysis-uncontrolled-hypertensive-patients-included-global

Zeijen VJM et al. Long-term safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 8-year results from the ACHIEVE study. Clinical Research in Cardiology. 2024.
https://link.springer.com/article/10.1007/s00392-024-02555-7

Mahfoud F, Azizi N, Caemen J et al. Real-world experience with ultrasound renal denervation utilizing home blood pressure monitoring: the Global Paradise System registry study design. Clinical Research in Cardiology. 2024.
https://link.springer.com/article/10.1007/s00392-023-02325-x

Bloch et al. 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. Hypertension Research. 2024.
https://www.recormedical.com/clinical-results-highlights/

Fengler et al. 6- and 12-Month Follow-Up From a Randomized Clinical Trial of Ultrasound vs Radiofrequency Renal Denervation (RADIOSOUND-HTN). JACC. 2023
https://www.jacc.org/doi/abs/10.1016/j.jcin.2022.10.058

V. Zeijen, TCT-210 Long-Term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-Year Results From the ACHIEVE Study. JACC. 2023.
https://www.jacc.org/doi/abs/10.1016/j.jacc.2023.09.217

Ktitane et al. Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. JAMA. 2023.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2802098

Azizi et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension The RADIANCE II Randomized Clinical Trial. JAMA. 2023.
https://jamanetwork.com/journals/jama/fullarticle/2801849

Rader et al. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention. 2022.
https://eurointervention.pcronline.com/article/durability-of-blood-pressure-reduction-after-ultrasound-renal-denervation-three-year-follow-up-of-the-treatment-arm-of-the-randomised-radiance-htn-solo-trial

Azizi et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single- blind, sham-controlled trial. Lancet. 2021. In press.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00788-1/abstract

Azizi et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019;139:2542–2553.
https://pubmed.ncbi.nlm.nih.gov/30880441

Daemen et al.  Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 12-month Results From the ACHIEVE Study. J Hypertens. 2019;37(9):1906-1912.
https://pubmed.ncbi.nlm.nih.gov/31045964

Fengler et al.  Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation. J Hypertens. 2018 Jul;36(7):1578-1584.
https://www.ncbi.nlm.nih.gov/pubmed/29652730

Azizi et al.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018 Jun 9;391(10137):2335-2345.
https://www.ncbi.nlm.nih.gov/pubmed/29803590

Mauri et al.  A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018 Jan;195:115-129.
https://www.ncbi.nlm.nih.gov/pubmed/29224639

Fengler et al.  Ultrasound-based renal sympathetic denervation for the treatment of therapy-resistant hypertension: a single-center experience. J Hypertens. 2017 Jun;35(6):1310-1317.
https://www.ncbi.nlm.nih.gov/pubmed/28441700

Stiermaier et al.  Endovascular ultrasound for renal sympathetic denervation in patients with therapy-resistant hypertension not responding to radiofrequency renal sympathetic denervation. EuroIntervention. 2016 Jun 12;12(2):e282-9.
https://www.ncbi.nlm.nih.gov/pubmed/27290688

Daemen et al.  First-in-man radial access renal denervation with the ReCor Radiance catheter. EuroIntervention. 2015 Feb;10(10):1209-12.
https://www.ncbi.nlm.nih.gov/pubmed/25493912

Pathak et al. Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity. EuroIntervention. 2015 Aug;11(4):477-84.
https://www.ncbi.nlm.nih.gov/pubmed/26298415

Fengler et al. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). Circulation. 2019 Jan 29;139(5):590-600.
https://pubmed.ncbi.nlm.nih.gov/30586691

Sakakura et al. Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound: a next-generation approach for treating sympathetic overactivity EuroIntervention. 2015 Feb;10(10):1230-8.
https://pubmed.ncbi.nlm.nih.gov/25349043

Renal Denervation Clinical Evidence And Basic Science

Böhm et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451.
https://pubmed.ncbi.nlm.nih.gov/28859944/

Schmieder et al.  European Society of Hypertension position paper on renal denervation 2018. J Hypertens. 2018 Oct;36(10):2042-2048.
https://www.ncbi.nlm.nih.gov/pubmed/30015759

Schlaich et al.  Renal Denervation—Ready for Prime Time!? The Steep SPYRAL Stairs to RADIANCE in Hypertension Treatment. Hypertension. 2018 Aug;72(2):287-290
https://www.ncbi.nlm.nih.gov/pubmed/29941510

Kandzari et al.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018 Jun 9;391(10137):2346-2355.
https://www.ncbi.nlm.nih.gov/pubmed/29803589

Townsend et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017 Nov 11;390(10108):2160-2170.
https://www.ncbi.nlm.nih.gov/pubmed/28859944

Azizi et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015 May 16;385(9981):1957-65.
https://www.ncbi.nlm.nih.gov/pubmed/25631070

Völz et al.  Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation. J Hypertens. 2018 Jan;36(1):151-158.
https://www.ncbi.nlm.nih.gov/pubmed/29210862

Fengler et al.  Pulse Wave Velocity Predicts Response to Renal Denervation in Isolated Systolic Hypertension. J Am Heart Assoc. 2017 May 17;6(5).
https://www.ncbi.nlm.nih.gov/pubmed/28515119

Kandzari et al.  The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J. 2016 Jan;171(1):82-91.
https://www.ncbi.nlm.nih.gov/pubmed/26699604

Mahfoud et al.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017 Nov 21;38(44):3272-3281.
https://www.ncbi.nlm.nih.gov/pubmed/28475773

Mahfoud et al.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015 Sep 1;36(33):2219-27.
https://www.ncbi.nlm.nih.gov/pubmed/25990344

Sakakura et al.  Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound: a next-generation approach for treating sympathetic overactivity. EuroIntervention 2015; 10: 1230–8.
https://www.ncbi.nlm.nih.gov/pubmed/25349043